NCT06726356 Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.
| NCT ID | NCT06726356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Ningbo University |
| Condition | Bronchiectasis with Acute Exacerbation |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-08-14 |
| Primary Completion | 2025-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2024-08-14 with a primary completion date of 2025-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bronchiectasis is a clinical syndrome characterised by chronic cough, profuse sputum and/or intermittent haemoptysis, with or without shortness of breath and respiratory failure of varying severity, and abnormal thickening and dilatation of the bronchial walls as seen on lung imaging. Nebulised inhalation of N-acetylcysteine has been shown to significantly improve symptoms, shorten the length of hospital stay, reduce the rate of re-hospitalisation within six months, and improve lung function in patients with bronchiectasis with a high degree of safety. There have been no studies on the efficacy and safety of bronchoscopic irrigation with N-acetylcysteine solution in the treatment of bronchiectasis. The aim of this study was to investigate whether bronchoscopic acetylcysteine lavage combined with conventional treatment is more beneficial to patients with bronchiectasis than conventional treatment combined with conventional bronchoalveolar lavage and conventional treatment without bronchoscopy, respectively.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years and ≤80 years; 2. Chest CT suggestive of bronchiectasis; 3. meet the criteria for an acute exacerbation of bronchiectasis with symptoms such as cough, sputum, chest tightness or wheezing, and c. Patients who meet the criteria for an acute exacerbation of bronchiectasis with symptoms of cough, sputum, chest tightness or wheezing and who consent to bronchoscopy with bronchoalveolar lavage 4. patients who agreed to participate in the study and signed an informed consent form; Exclusion Criteria: 1. Severe cardiopulmonary diseases, coagulation disorders, poor tolerance to anaesthesia, psychiatric disorders or severe neuroses that are contraindications to bronchoscopy; 2. Intraoperative findings of decreased SPO2 or inability to tolerate bronchoscopy or inability to tolerate further bronchoalveolar lavage; 3. Inability to co-operate with the study for any reason or in the opinion of the investigator, inappropriate for inclusion in the study for other reasons; 4. Bronchoscopy of patients with significant intra-airway haemorrhage who may be at risk of exacerbation due to bronchoalveolar lavage; 5. Patients with acetylcysteine allergy; 6. Missing information;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06726356 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Bronchiectasis with Acute Exacerbation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06726356 currently recruiting?
Yes, NCT06726356 is actively recruiting participants. Contact the research team at leonczb@163.com for enrollment information.
Where is the NCT06726356 trial being conducted?
This trial is being conducted at Ningbo, China.
Who is sponsoring the NCT06726356 clinical trial?
NCT06726356 is sponsored by First Affiliated Hospital of Ningbo University. The trial plans to enroll 180 participants.